Medicare covers TSH (thyroid-stimulating hormone) testing when a provider documents a diagnosis that establishes medical necessity, not as a routine screening test for people who feel fine. The qualifying diagnoses span a wide range: known thyroid disorders, suspicious symptoms like unexplained fatigue or weight changes, monitoring of medications that affect the thyroid, and several other clinical situations. Because Medicare relies on diagnosis codes to decide whether a lab test is covered, understanding which codes apply can be the difference between a fully covered blood draw and a surprise bill.
How Medicare Decides Whether to Pay for a TSH Test
Medicare does not maintain a single national list of approved diagnoses for TSH testing. Instead, coverage is largely governed by Local Coverage Determinations (LCDs) published by Medicare Administrative Contractors (MACs), the regional entities that process claims on Medicare’s behalf. Each MAC publishes its own LCD for thyroid testing, which includes a list of ICD-10 diagnosis codes considered medically necessary. The lists overlap heavily across regions, but small differences exist, so a diagnosis that sails through in one state could occasionally trigger a review in another.
The underlying principle is consistent everywhere: Medicare pays for TSH testing when there is a documented clinical reason to check thyroid function. That clinical reason gets translated into an ICD-10 code on the lab order. If the code matches the MAC’s approved list, the claim is paid. If it does not, the claim is denied, and you could be responsible for the cost unless an Advance Beneficiary Notice of Noncoverage (ABN) was signed beforehand.
Thyroid Disorders Themselves
The most straightforward qualifying diagnoses are thyroid conditions that have already been identified. If you carry any of the following diagnoses, TSH testing to monitor or manage the condition is covered:
- Hypothyroidism: This includes autoimmune hypothyroidism (Hashimoto’s disease), post-surgical hypothyroidism after a thyroidectomy, hypothyroidism resulting from medication or radiation, and unspecified hypothyroidism. Patients on levothyroxine or other thyroid hormone replacement need periodic TSH checks to ensure their dose is correct.
- Hyperthyroidism: Graves’ disease, toxic multinodular goiter, and other forms of overactive thyroid all qualify. Monitoring during treatment with antithyroid drugs like methimazole is a standard use of TSH testing.
- Thyroiditis: Subacute, chronic, and autoimmune thyroiditis are covered diagnoses. Thyroiditis can cause thyroid levels to swing unpredictably, making TSH monitoring medically necessary.
- Goiter and thyroid nodules: An enlarged thyroid or nodules discovered on exam or imaging justify TSH testing to assess whether the structural abnormality is affecting hormone production.
- Thyroid cancer or history of thyroid cancer: Post-treatment surveillance for thyroid malignancies routinely includes TSH monitoring, sometimes with the goal of keeping TSH suppressed to reduce recurrence risk.
For patients already diagnosed with a thyroid condition, repeated TSH tests over time are expected. Medicare generally covers these follow-up tests as long as the ordering provider documents the ongoing diagnosis.
Signs and Symptoms That Justify Testing
You do not need a confirmed thyroid diagnosis for Medicare to cover TSH testing. A range of signs and symptoms can establish medical necessity when the provider suspects thyroid dysfunction might be the cause. These symptom-based diagnoses are where coverage questions come up most often, because they are less obviously tied to the thyroid than a diagnosis of hypothyroidism would be.
Common symptom codes accepted on most MAC lists include:
- Fatigue: Unexplained, persistent tiredness is one of the most frequent reasons providers order a TSH. The ICD-10 code for fatigue or malaise typically appears on every MAC’s approved list.
- Unexplained weight changes: Both unintentional weight gain and unexplained weight loss can signal thyroid dysfunction and are recognized as supporting diagnoses.
- Hair loss: Alopecia that is not clearly related to another condition can justify checking thyroid levels.
- Menstrual irregularities: Abnormal uterine bleeding, amenorrhea, or other menstrual disturbances are accepted because thyroid hormones directly influence reproductive function.
- Depression and anxiety: Mood disorders can be symptoms of both hypothyroidism and hyperthyroidism. When a provider is evaluating a new onset of depression, checking TSH is a standard part of the workup, and Medicare recognizes the diagnosis code for the mood symptoms.
- Palpitations and tachycardia: A racing or irregular heartbeat can be a sign of hyperthyroidism, so these cardiovascular symptoms often qualify.
- Constipation or diarrhea: Gastrointestinal symptoms that might be thyroid-related are generally accepted, though the provider needs to document the clinical reasoning.
- Cold or heat intolerance: Feeling abnormally cold or overheated without clear cause is a classic thyroid symptom and is recognized on most LCD lists.
The key with symptom-based testing is documentation. The provider must note why thyroid dysfunction is a reasonable consideration given the patient’s presentation. A vague “check thyroid” order with no supporting diagnosis is the scenario most likely to result in a denied claim.
Medication Monitoring
Several medications can disrupt thyroid function, and monitoring TSH while taking them is considered medically necessary. The two most commonly cited are lithium and amiodarone. Lithium, used for bipolar disorder, causes hypothyroidism in a meaningful percentage of patients, so periodic TSH testing is standard practice. Amiodarone, a cardiac antiarrhythmic drug, can cause either hypothyroidism or hyperthyroidism due to its high iodine content, making TSH monitoring essential.
Other medications that may warrant TSH monitoring include certain immunotherapy drugs (particularly immune checkpoint inhibitors used in cancer treatment, which can trigger thyroiditis), interferon-alpha, and tyrosine kinase inhibitors. When the ordering provider documents the relevant medication and its known risk to thyroid function, the TSH test is covered. The diagnosis code in these situations is often “adverse effect of drug” or “long-term use of medication” combined with a thyroid-related code.
Other Clinical Scenarios That Qualify
Beyond direct thyroid disease, symptoms, and medication monitoring, several other clinical contexts support Medicare coverage for TSH testing:
- Pituitary disorders: Because TSH is produced by the pituitary gland, conditions affecting the pituitary (tumors, post-surgical follow-up, hypopituitarism) justify TSH testing as part of the broader hormonal evaluation.
- Hyperlipidemia workup: Elevated cholesterol that does not respond as expected to treatment can prompt a TSH check, because hypothyroidism is a treatable cause of high lipids. The hyperlipidemia diagnosis code itself often appears on MAC-approved lists for TSH.
- Infertility evaluation: Thyroid dysfunction is a recognized contributor to difficulty conceiving, and TSH is a standard part of an infertility workup.
- Newborn screening follow-up: While neonatal screening is its own program, follow-up TSH testing for infants flagged at birth is covered.
- Down syndrome: People with Down syndrome have a higher prevalence of thyroid dysfunction, and periodic screening is part of recommended care, giving providers a qualifying diagnosis for TSH orders.
- Type 1 diabetes: Autoimmune thyroid disease co-occurs at elevated rates in people with type 1 diabetes, so TSH monitoring in this population has a clear clinical basis.
In practice, the universe of qualifying diagnoses is broad enough that most clinical situations where a provider has a genuine reason to suspect thyroid involvement will be covered. The coverage gaps tend to appear in truly asymptomatic screening, not in symptomatic workups.
Why Routine Screening Is Not Covered
The distinction that catches many people off guard is that Medicare generally does not cover TSH testing as a screening test in adults who have no symptoms, no risk factors, and no prior thyroid disease. This is not arbitrary stinginess. It reflects the position of the U.S. Preventive Services Task Force, which has concluded that the current evidence is insufficient to determine whether screening asymptomatic, nonpregnant adults for thyroid dysfunction produces a net benefit.1PubMed. Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement Without a clear recommendation in favor of screening, Medicare’s coverage framework treats the test as not medically necessary in that context.
This creates a practical gap: thyroid disorders can develop slowly, and some people with early hypothyroidism or hyperthyroidism may not recognize their symptoms as abnormal. They might attribute fatigue to aging or weight gain to diet. In those situations, the condition exists but no one has documented a symptom code. Some providers work around this by documenting whatever symptoms the patient does report, even if the patient considers them minor. Others simply inform the patient that the test might not be covered and offer an ABN.
It is worth noting that certain professional societies, including the American Thyroid Association, have recommended thyroid screening in adults over a certain age, particularly women, even when the USPSTF has not endorsed that approach. Medicare’s coverage rules follow CMS policy and MAC determinations, not individual society guidelines, so these recommendations alone do not guarantee coverage.
What Happens When a Claim Is Denied
If a TSH test is ordered with a diagnosis code that does not appear on the MAC’s approved list, the claim will be denied. What happens next depends on whether the provider gave you an ABN before the test was drawn.
An ABN is a form that warns you in advance that Medicare might not pay for a specific service and asks whether you still want it, understanding you could be financially responsible. If you signed an ABN and the claim is denied, you pay. If no ABN was provided, the lab or provider typically cannot bill you for the cost, and they absorb the loss. This is why labs and provider offices are often careful about checking diagnosis codes before drawing thyroid panels.
If you believe a denial was wrong, meaning you do have a qualifying diagnosis that was simply not coded correctly on the order, you can appeal. The first step is usually contacting the provider’s office to see whether the claim can be resubmitted with a corrected diagnosis code. Many denials for TSH testing are coding errors rather than true coverage failures.
How Often Medicare Covers Repeat TSH Tests
Medicare does not specify a fixed frequency for TSH testing in most situations. The general standard is that repeat testing must be medically necessary, which means there should be a clinical reason for each test. In practice, the accepted norms depend on the underlying condition:
- Stable hypothyroidism on a consistent dose: Once or twice a year is the typical pattern. Most MACs will not question an annual TSH for a patient on thyroid hormone replacement.
- Dose adjustments: After a change in levothyroxine dose, a follow-up TSH in roughly six to eight weeks is standard, because that is how long it takes for levels to stabilize. Multiple tests within a few months during dose titration are covered.
- Hyperthyroidism under active treatment: More frequent monitoring, sometimes every four to six weeks, is expected during the early phase of antithyroid drug therapy.
- Thyroid cancer surveillance: The monitoring schedule is driven by oncology guidelines and can involve TSH checks every few months in the early years after treatment.
- Medication monitoring: For patients on lithium or amiodarone, a TSH check every six to twelve months is a common interval, with more frequent testing if abnormalities appear.
Problems tend to arise when TSH is ordered very frequently without clear documentation of why. A patient getting monthly TSH tests for years with no dose changes and a stable condition may trigger a review. The solution is straightforward documentation: the ordering provider notes why each test was needed.
When Biotin Supplements Complicate Results
An issue that has become more relevant as supplement use has grown is biotin interference with thyroid lab tests. Biotin, a B vitamin sold in high-dose supplements for hair, skin, and nail health, can interfere with certain immunoassay platforms used to measure TSH, free T3, and free T4. The interference can produce falsely low TSH readings alongside falsely elevated thyroid hormone levels, creating a lab picture that looks like hyperthyroidism or Graves’ disease in a person whose thyroid is actually normal.2PubMed Central. Assessment of biotin interference in thyroid function tests
This matters for Medicare coverage in a roundabout way: a falsely abnormal TSH triggered by biotin could lead to additional testing, specialist referrals, and imaging that would not have been needed if the patient had simply stopped the supplement before the blood draw. All of those downstream tests carry their own coverage questions and costs. If you take biotin supplements and are scheduled for thyroid bloodwork, most labs now recommend stopping the supplement at least 48 to 72 hours before the draw. Mentioning biotin use to your provider before the test is ordered can prevent a cascade of unnecessary and potentially costly follow-up.
TSH as Part of a Panel Versus a Standalone Test
Providers sometimes order TSH alone and sometimes as part of a broader thyroid panel that includes free T4, free T3, or thyroid antibodies. Medicare coverage rules apply to each component individually. A TSH test might be covered under a given diagnosis, but the additional free T3 or thyroid peroxidase antibody test might not be, depending on the clinical context and the MAC’s LCD.
For initial evaluation of a suspected thyroid problem, TSH and free T4 together are the standard combination and are generally covered under most qualifying diagnoses. Free T3 and antibody tests tend to have a narrower set of approved diagnoses, often limited to known or strongly suspected hyperthyroidism, Graves’ disease, or thyroiditis. Ordering a full thyroid panel “just to be thorough” on a patient whose only symptom is mild fatigue may result in the TSH and free T4 being covered while the T3 and antibody tests are denied.
Providers who are mindful of this often order TSH first, then add additional tests only if the TSH result comes back abnormal, which both follows clinical logic and aligns with Medicare’s medical necessity framework. If you see a thyroid panel on your lab order and are concerned about coverage, asking the provider which components are being ordered and why can help you understand your potential out-of-pocket exposure before the blood is drawn.